Capital Advisors Ltd’s Roivant Sciences ROIV Stock Holding History

Capital Advisors Ltd’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11	Closed	–	–	1549
2024 Q4	$0	Buy	+11	New	+$130	﹤0.01%	1546

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Capital Advisors Ltd's ROIV Position: Q1 2025 in Review

Capital Advisors Ltd sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 11 shares.

Capital Advisors Ltd first reported a position in ROIV in Q4 2024 and held it in 1 quarter. The position peaked at $0 in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

Capital Advisors Ltd reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
Capital Advisors Ltd sold 11 Roivant Sciences shares in Q1 2025.
Capital Advisors Ltd first reported a position in Roivant Sciences in Q4 2024 and held it in 1 quarter.
Capital Advisors Ltd's Roivant Sciences position peaked at $0 in Q4 2024.
312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on Capital Advisors Ltd's 13F filing for Q1 2025, filed 15 Apr 2025.